Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
19
datasets available to search
ShareScore release 0.9.0
Dataset results
19 results for “TMB”
FT37 Marzoli TMB 15-key tenoroon: measurements, photos, endoscopic video
<p>Dataset of FT37 Marzoli TMB 15-key tenoroon containing detailed external and internal measurements, photos, and an endoscopic video. </p>
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
ClinicalTrials.gov study NCT03668119. IPD Sharing: NO. Countries: 17. Publications: 1.
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
ClinicalTrials.gov study NCT05295732. IPD Sharing: NO. Countries: 5. Publications: 0.
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
ClinicalTrials.gov study NCT04154293. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Subclonal mutational load predicts survival and response to immunotherapy in cancers with low to moderate TMB
<p>Here we provide the downloadable links of subclonal reconstruction results by <strong>CliPP</strong>, on both <strong>TCGA</strong> and <strong>PCAWG</strong> datasets. We also provide the source of our in-house simulation data (<strong>CliPPSim4k</strong>), along with a comparison between CliPP and PhyloWGS.</p> <p>For more detailed information about the data, please refer to our paper: <a href="https://www.biorxiv.org/content/10.1101/2024.07.03.601939v1" target="_new" rel="noopener">https://www.biorxiv.org/content/10.1101/2024.07.03.601939v1</a> or visit our web app: <a href="https://bioinformatics.mdanderson.org/apps/CliPP/" target="_new" rel="noopener">https://bioinformatics.mdanderson.org/apps/CliPP/</a></p>
Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
<p>Wallen ZD, Ko H, Nesline MK, Tierno M, Roos A, Schnettler E, Husain H, Sathyan P, Caveney B, Eisenberg M, Severson EA, Ramkissoon SH. <strong>Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic.</strong> <em>Front Oncol.</em> 2024 Nov 5;14:1473327. doi: <a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1473327">10.3389/fonc.2024.1473327</a>.</p> <p><strong>ABSTRACT</strong></p> <p><strong>Introduction: </strong>Matching patients to an effective targeted therapy or immunotherapy is a challenge for <br>advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one <br>marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CGP) can <br>simultaneously assess NSCLC tumors for hundreds of genomic biomarkers and markers for immunotherapy <br>response, leading to quicker and more precise matches to therapeutics. <strong>Methods: </strong>In this study, we performed <br>CGP on 7,606 patients with advanced or metastatic NSCLC using the Illumina TruSight Oncology 500 (TSO <br>500) CGP assay to show its coverage and utility in detecting known and novel features of NSCLC. <strong>Results: </strong><br>Testing revealed distinct genomic profiles of lung adenocarcinoma and squamous cell carcinomas and <br>detected variants with a current targeted therapy or clinical trial in >72% of patient tumors. Known associations <br>between genomic alterations and immunotherapy markers were observed including significantly lower TMB <br>levels in tumors with therapy-associated alterations and significantly higher PD-L1 levels in tumors with ALK, <br>MET, BRAF, or ROS1 driver mutations. Co-occurrence analysis followed by network analysis with gene <br>module detection revealed known and novel co-occurrences between genomic alterations. Further, certain <br>modules of genes with co-occurring genomic alterations had dose-dependent relationships with histology and <br>increasing or decreasing levels of PD-L1 and TMB, suggesting a complex relationship between PD-L1, TMB, <br>and genomic alterations in these gene modules. <strong>Discussion:</strong> This study is the largest clinical study to date <br>utilizing the TSO 500. It provides an opportunity to further characterize the landscape of NSCLC using this <br>newer technology and show its clinical utility in detecting known and novel facets of NSCLC to inform treatment <br>decision-making.</p> <p><strong>DATA AVAILABILITY</strong></p> <p>The data and code presented in the study are deposited in this Zenodo repository, accession number <br>13137232 (<a href="https://zenodo.org/record/13137232">https://zenodo.org/record/13137232</a>). Raw sequencing data were derived from routine clinical testing of real-world patients and cannot be shared publicly. Further data inquiries can be directed to the corresponding <br>author. </p>
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high)
ClinicalTrials.gov study NCT05770102. IPD Sharing: YES. Countries: 1. Publications: 0.
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
ClinicalTrials.gov study NCT03638297. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
ClinicalTrials.gov study NCT04059887. IPD Sharing: NO. Countries: 1. Publications: 2.
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
ClinicalTrials.gov study NCT05275998. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsat
ClinicalTrials.gov study NCT06331598. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
ClinicalTrials.gov study NCT03110549. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Chemotherapy on TMB in NSCLC
ClinicalTrials.gov study NCT03683407. IPD Sharing: NO. Countries: 1. Publications: 0.
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
ClinicalTrials.gov study NCT04027387. IPD Sharing: NO. Countries: 2. Publications: 0.
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
ClinicalTrials.gov study NCT06365840. IPD Sharing: NO. Countries: 1. Publications: 0.
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
ClinicalTrials.gov study NCT06227728. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
ClinicalTrials.gov study NCT04052113. IPD Sharing: NO. Countries: 1. Publications: 0.
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
ClinicalTrials.gov study NCT07215468. IPD Sharing: NO. Countries: 1. Publications: 0.
TMB_Immune_Landscape_Glioma
Dataset for Tumor Mutation Burden (TMB) landscape in glioblastoma.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.